Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

The use of active surveillance or watchful waiting increased by more than twofold overall between 2010 and 2020 among patients with intermediate-risk prostate cancer. Current guidelines support active ...

In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.

In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.

SBRT reduced biochemical failure and acute GU toxicity compared with HDR brachytherapy in intermediate-risk prostate cancer. Read more about the findings.

Please provide your email address to receive an email when new articles are posted on . Men with low- or intermediate-risk prostate cancer achieved similar quality-of-life outcomes whether they ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced patient-reported side effects compared to longer courses of radiation, according to ...

New Corewell Health™ research suggests an MRI scan can help predict whether patients with intermediate-risk prostate cancer (cancer confined to the entire prostate) may have more aggressive cancer in ...

The average age of men who get diagnosed is 67.

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

It’s the second most common type of cancer among men and affects 1 in every 8 men in the United States. September is Prostate Cancer Awareness Month, and the American Cancer Society says this type of ...